8-K: Clene Submits Positive CNM-Au8 Data to FDA for ALS Treatment, Showing Significant Clinical Improvements

Clene Inc. has submitted new biomarker and clinical efficacy data to the FDA for its CNM-Au8 treatment for ALS, demonstrating significant improvements in survival and functional status for a subset of patients.

Summary

• Clene Inc. has announced the submission of new data to the FDA regarding their CNM-Au8 treatment for amyotrophic lateral sclerosis (ALS).
• The data includes post-hoc analyses from two Phase 2 clinical trials.
• The submission is intended to support discussions with the FDA for an accelerated approval pathway.
• The data focuses on a subset of patients called 'CNM-Au8 NfL Responders' who showed a 28% reduction in neurofilament light (NfL) levels compared to baseline.
• These responders also demonstrated improved survival, less decline in functional status, and better combined function and survival scores compared to non-responders.
• Long-term treatment with CNM-Au8 30mg showed a significant decrease in the risk of mortality compared to multiple natural history controls.
• The treatment also showed improvements in nicotinamide adenine dinucleotide (NAD) and glutathione levels, supporting a dual mechanism of action.
• Over 650 patient years of safety data show no significant safety concerns related to CNM-Au8.

Sentiment

Score: 8

Explanation: The document presents very positive clinical data for CNM-Au8, with significant improvements in survival and functional status for ALS patients. The strong safety profile and the potential for accelerated approval contribute to a high sentiment score.

Positives

• CNM-Au8 treatment demonstrated significant clinical improvements in survival, functional status, and combined function and survival for NfL responders.
• Long-term treatment with CNM-Au8 30mg showed a substantial reduction in mortality risk compared to multiple control groups.
• The treatment showed improvements in key biomarkers like NAD and glutathione, supporting its mechanism of action.
• The safety profile of CNM-Au8 remains strong with no significant safety concerns identified.
• The data supports the potential for an accelerated approval pathway for CNM-Au8.

Risks

• The company's ability to demonstrate the efficacy and safety of its drug candidates is subject to regulatory approval.
• Clinical results may not support further development or marketing approval.
• Actions of regulatory agencies may affect the initiation, timing, and progress of clinical trials and marketing approval.
• The company has a limited operating history and may need additional funding for operations.
• The company's ability to achieve commercial success for its drug candidates, if approved, is not guaranteed.

Future Outlook

The company plans to discuss the new CNM-Au8 data with the FDA to explore an accelerated approval pathway. They also plan to use their website to disseminate future updates to the Corporate Presentation.

Management Comments

• Merit Cudkowicz, M.D., stated that the strong safety profile of CNM-Au8, linked to survival evidence, supports proceeding to a Phase 3 clinical trial and regulatory discussions.
• Rob Etherington, CEO and President of Clene, expressed hope that ALS patients will benefit from the drug sooner rather than later.

Industry Context

This announcement is significant in the context of the ongoing search for effective treatments for ALS, a devastating neurodegenerative disease. The positive data from Clene's CNM-Au8 could represent a potential breakthrough in the field, especially given the lack of effective treatments currently available.

Comparison to Industry Standards

• The use of the PRO-ACT database, the ALS/MND Natural History Consortium (NHC), and the Australian MiNDAUS registry for control data is a common practice in ALS research, providing a robust comparison for the CNM-Au8 results.
• The hazard ratios reported for survival improvements are significant when compared to other ALS treatments, which often show only modest benefits.
• The focus on NfL as a biomarker is consistent with current research trends in ALS, where NfL is increasingly recognized as a key indicator of disease progression and treatment response.
• The dual mechanism of action targeting mitochondrial function and oxidative stress is a novel approach compared to many other ALS therapies that focus on single pathways.

Stakeholder Impact

• Shareholders may react positively to the strong clinical data and the potential for accelerated approval.
• ALS patients and their families may have increased hope for a new treatment option.
• Employees of Clene may be motivated by the positive results and the potential for commercial success.
• The medical community may be interested in the new data and the potential for CNM-Au8 to become a standard treatment for ALS.

Next Steps

• The company plans to have a Type C meeting with the FDA in the third quarter of 2024 to discuss an accelerated approval pathway.
• The company may update the corporate presentation on its website.

Key Dates

Keywords

CNM-Au8, ALS, amyotrophic lateral sclerosis, FDA, biomarker, clinical efficacy, neurofilament light, NfL, survival, functional status, mitochondrial health, neurodegenerative diseases, accelerated approval